Examples
Worked examples
- Is an instance
An assistant professor four years past their PhD applies for DP2 with an unconventional, not-yet-validated imaging method, since DP2 review weighs creativity and track record over preliminary data.
- Is an instance
A physician-scientist within eight years of residency, without a prior major NIH award, is funded directly through a single five-year DP2 award covering both salary support and project costs.
Counter-examples
Looks similar, but isn't
- Not an instance
A researcher 14 years past their doctoral degree, with no qualifying ESI extension, is ineligible for DP2 regardless of the proposal's novelty and must compete under a mechanism without an early-career restriction, such as R01.
- Not an instance
An investigator wanting a short, two-year feasibility test before a larger program should apply for R21, not DP2 — DP2 funds a full five-year independent program, not a pilot step.
Editorial commentary
The NIH Director’s New Innovator Award (DP2) is a National Institutes of Health grant mechanism created for early-career investigators who propose exceptionally creative, high-risk, high-reward research. It is one of four award programs administered under the NIH Common Fund’s High-Risk, High-Reward Research (HRHR) program, alongside the Pioneer Award (DP1), the Transformative Research Award, and the Early Independence Award (DP5). Unlike the standard R01 mechanism, DP2 review does not require extensive preliminary data — applications are judged primarily on the investigator’s creativity and the boldness of the proposed approach.
Origin and purpose
NIH established the New Innovator Award in 2007 to address a gap in its funding portfolio: early-stage investigators with unconventional ideas were struggling to compete for traditional R01 funding, which is typically hypothesis-driven and expects supporting pilot data. DP2 was designed specifically to fund investigators, not just projects — proposals in any scientific area relevant to the NIH mission (behavioral, social, biomedical, applied, or formal sciences; basic, translational, or clinical research) are eligible, provided the applicant meets the program’s early-career eligibility rules.
Eligibility
Applicants must qualify as an Early Stage Investigator (ESI) — an NIH New Investigator within 10 years of completing a terminal research degree or, for clinician-scientists, within 10 years of completing medical residency or the equivalent, and who has not yet received a substantial independent NIH research award. This 10-year window can be extended for documented, qualifying events (e.g., family leave, disability, extended clinical training). Because eligibility is investigator-based rather than project-based, DP2 is structurally different from mechanisms like R01 and R21, which carry no early-career restriction at all.
Funding and duration
DP2 provides a single award covering both the research project and, in many cases, the investigator’s own salary support, over a five-year project period. Historically the program funded up to $1.5 million in total direct costs across the five years; more recent Requests for Applications (for example, RFA-RM-27-002) have listed total direct costs up to $2,375,000 over the five-year period. The exact funding ceiling is set fiscal year to fiscal year in the current Notice of Funding Opportunity (NOFO), so applicants and research administrators should always confirm the active solicitation’s figures rather than relying on a prior year’s cap. Only one competing application per investigator is typically permitted per annual cycle, and NIH funds a small, competitive cohort of awards each year across all Institutes and Centers.
How DP2 differs from R01 and R21
- Eligibility: DP2 requires Early Stage Investigator status; R01 and R21 have no career-stage restriction.
- Preliminary data: DP2 review emphasizes investigator creativity and does not require extensive preliminary data; a standard R01 application is expected to include supporting pilot data; R21 also does not require preliminary data but is scoped as a short exploratory step, not a full independent program.
- Duration and structure: DP2 is a single five-year award (often including salary support); R01 project periods are commonly awarded up to five years and can be competitively renewed; R21 is capped at two years with no renewal mechanism.
- Budget: DP2’s total direct-cost ceiling (historically $1.5M, more recently up to $2.375M per the current NOFO) is substantially larger than R21’s $275,000 direct-cost cap over its two-year period.
- Review focus: DP2 applications are evaluated as much on the investigator’s track record of creativity and the boldness of the idea as on a conventional specific-aims/preliminary-data framework used for R01 and R21 study section review.
See the CASRAI comparison of R01 vs. R21 for a full breakdown of those two more conventional research-project mechanisms, and the NIH grants overview guide for how DP2 fits into the broader landscape of NIH activity codes.
Worked examples
Example 1. An assistant professor four years past their PhD develops an unconventional single-cell imaging approach with no pilot data yet collected. Because a standard R01 reviewer would expect preliminary evidence the method works, the investigator instead applies for DP2, where the review panel weighs the originality of the approach and the applicant’s track record of creative problem-solving rather than requiring proof-of-concept data up front.
Example 2. A physician-scientist within eight years of completing residency, who has not yet held a major independent NIH award, proposes an interdisciplinary computational approach to a long-standing clinical problem. Rather than first seeking a smaller exploratory award, they apply directly for DP2, which — if funded — provides a single five-year award covering both salary support and project costs for the full program of work.
Counter-examples
Not a DP2 case 1. A researcher 14 years past completing their doctoral degree, with no qualifying extension on file, does not meet the Early Stage Investigator window and is not eligible for DP2 regardless of how novel the proposed research is — they would instead compete for R01 or another mechanism without an early-career restriction.
Not a DP2 case 2. An investigator who wants two years of funding to test the feasibility of a new idea before committing to a larger program should apply for R21, not DP2. DP2 is not a short pilot or stepping-stone mechanism — it funds a full five-year independent research program, and its budget and review process are built around that commitment, not a limited feasibility test.
Related terms
Machine-readable encodings
Use in your systems
<role vocab="credit"
vocab-identifier="https://casrai.org/dictionary/"
vocab-term="NIH Director’s New Innovator Award (DP2)"
vocab-term-identifier="https://casrai.org/dictionary/term/nih-dp2-new-innovator-award" />{
"@context": "https://schema.org",
"@type": "DefinedTerm",
"@id": "https://casrai.org/dictionary/term/nih-dp2-new-innovator-award",
"name": "NIH Director's New Innovator Award (DP2)",
"identifier": "https://casrai.org/dictionary/term/nih-dp2-new-innovator-award",
"description": "The NIH Director's New Innovator Award (DP2) is a Common Fund High-Risk, High-Reward Research grant that funds early-career investigators (Early Stage Investigators, within 10 years of their terminal degree or clinical training) proposing exceptionally creative, high-risk research, without requiring the extensive preliminary data a standard R01 application expects. It provides a single award, historically up to $1.5 million and more recently up to $2.375 million in total direct costs, over a five-year project period.",
"inDefinedTermSet": "https://casrai.org/dictionary/domain/funding-finance#set",
"url": "https://casrai.org/dictionary/term/nih-dp2-new-innovator-award",
"sameAs": [],
"license": "https://creativecommons.org/licenses/by/4.0/",
"publisher": {
"@id": "https://casrai.org/#organization"
},
"dateModified": "2026-07-23T09:33:42",
"inLanguage": "en"
}
